Can I read Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination on EtoBox?

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination by Azam Safary; Kamal Esalatmanesh; Amir Taher Eftekharsadat; Mohammad-Reza Jafari Nakjavani; Alireza Khabbazi is a Immunology and Microbiology article available to read on EtoBox.

What is Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination about?

Vaccination against COVID-19 is one of the critical tools to provide herd immunity, reduce mortality, and control the pandemic worldwide. Despite the safety of vaccination against SARS-CoV-2 in the healthy population, a minority of people may develop rare post-vaccine adverse reactions such as autoimmune syndromes. The current study aimed to identify and present a series of patients with de-novo autoimmune rheumatic diseases (ARDs) associated with COVID-19 vaccines. Inclusion criteria were the onset of ARDs symptoms at ~3-4 weeks postvaccination, age ≥ 16, no previous history of ARDs, meeting the classification criteria for one of the ARDs, and staying in the follow-up. The most commonly used vaccines in patients were Sinopharm [7 cases (50%)] and AstraZeneca [6 cases (42.9%)]. ARDs were significantly more common in subjects who received the AstraZeneca vaccine than in those who received other vaccines. Based on the results, patients were diagnosed with rheumatoid arthritis or one of its subtypes (5 cases), vasculitis (4 cases), systemic lupus erythematosus (3 cases), and peripheral seronegative spondyloarthritis (2 cases). Except for one patient with self-limitation of ARD, others

Who reads Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination?

Author

Azam Safary; Kamal Esalatmanesh; Amir Taher Eftekharsadat; Mohammad-Reza Jafari Nakjavani; Alireza Khabbazi

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Immunology and Microbiology (Life Sciences)